On the morning of May 28, 2010, at 10 o'clock, Sunlight Pharmaceutical Co., Ltd. and Uria Pharmaceutical Group of Spain officially signed the joint venture project under the joint witness of the Wujin District Government, Benniu Town Government, leaders of various committees and offices, and senior management of both companies.

The Spanish Uria Pharmaceutical Group was founded in 1838 and has a history of 172 years. The group is the largest pharmaceutical company in Spain and a long-standing family owned enterprise, renowned in the European pharmaceutical industry.

Spain's Uria Pharmaceutical Group has strong new drug research and development capabilities, applying for over 100 world patents for new drug inventions. In the past 30 years, it has launched new drugs such as the anti allergic drugs Lupatadine and hypoglycemic glimepiride, covering treatment fields such as anti-inflammatory, antifungal infections, anti allergy, cardiovascular and cerebrovascular diseases, and autoimmune disorders.

he total investment of this joint venture project is 450 million yuan, of which 25 million euros is invested by Spain's Uria Group, and about 250 million yuan is invested by Changzhou Sunlight Pharmaceutical Co., Ltd. Both parties jointly develop and produce new drugs for the treatment of cardiovascular and cerebrovascular diseases, elderly diseases, and other diseases. In 2010, Spain's Uria Group invested 7.5 million euros, while Changzhou Sunlight Pharmaceutical Co., Ltd. invested 75 million yuan in development and production. It is expected to start construction in 2010 and put into operation in 2011, with an annual production of 400 million yuan. The second and third phases will be invested by Spain's Uria Group with an additional 7.5 million euros and 10 million euros, respectively. Changzhou Sunlight Pharmaceutical Co., Ltd. will invest 75 million yuan and 100 million yuan, and after completion, the annual production and sales volume will reach 2 billion yuan.

Zhang Jianxin, member of the Standing Committee of the Wujin District Committee and Executive Vice District Mayor, congratulated the signing of the project. He said that currently, our district is closely focusing on the three-year action plan of "upgrading traditional industries, doubling emerging industries, and accelerating modern service industries", further accelerating industrial transformation and upgrading, optimizing industrial structure, and enhancing comprehensive competitiveness. The formal signing of the cooperation project between Sunlight Pharmaceutical and Uria Pharmaceutical Group is a concrete manifestation of the implementation of the three-year action plan. I believe that with the strong new drug research and development capabilities of Uria Pharmaceutical Group, the enterprising spirit of Sunlight Pharmaceutical, and the high-quality services provided by our district, the joint venture project will definitely burst into strong vitality and become a new star in the five major industries in our district.

Zhang Jianxin stated that the signing of the project is the first step of cooperation between both parties. He hopes that both parties can accelerate the preparation work for the project commencement, start the project construction as soon as possible, put it into operation as soon as possible, and achieve the desired results.